Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib for High DSA Post-Kidney Transplant
NCT01349595Phase 2Terminated
- Start
- Dec 2011
- Primary completion
- Mar 2015
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in transplant glomerulopathy (TG), antibody mediated rejection (AMR). Started Dec 2011; status: terminated.
02
Drugs
bortezomib
03
Conditions
transplant glomerulopathy (TG)antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT01349595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01349595.